CareLit Fachartikel

Targeting the p53 tumor suppressor activity in glioblastomas using small molecule MDM2-inhibitor

P. Monfared, T. Viel, G. Schneider, Y. Waerzeggers, S. Rapic, B. Neumaier, H. Backes, A. Winkeler, A.H. Jacobs · Klinische Neurophysiologie · 2011 · Heft 03

Dokument
819477
CareLit-ID
Jahr
2011
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Klinische Neurophysiologie
Autor:innen
P. Monfared, T. Viel, G. Schneider, Y. Waerzeggers, S. Rapic, B. Neumaier, H. Backes, A. Winkeler, A.H. Jacobs
Ausgabe
Heft 03 / 2011
Seiten
–
Erschienen: 2011-03-10 00:00:00
ISSN
1434-0275
DOI
10.1055/s-0031-1272660

Zusammenfassung

Introduction: Targeted therapies that inhibit the MDM2-p53 interaction and the downstream RB-E2F signalling pathway have shown promising antitumor activity, but their efficacy in gliomas has not been investigated. Small-molecule MDM2 antagonists have been developed to specifically inhibit the MDM2-p53 interaction, thereby activating p53 signalling serving anti-tumor activity. Aims: To investigate the therapeutic potential of disrupting the MDM2-p53 interaction in human gliomas cells with various p53 status. We particularly followed whether MDM2-inhibition would sensitize gliomas to additional chemotherapy. Metho…

Schlagworte

Klinische Neurophysiologie